ProCE Banner Activity

Overview, Rationale, and Guidance on Testing for Rare Genomic Alterations in Advanced Thyroid Cancer

Slideset Download

Download these slides from a live symposium at ASCP 2022 featuring guidance from a pathologist on best practices for biomarker testing in advanced thyroid cancer along with the latest clinical evidence on targeted therapies available for the treatment of RET-altered and BRAF V600E–positive disease.

Released: September 13, 2022

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc, Blueprint Medicines and Genentech, a member of the Roche Group, and Lilly.

Bayer HealthCare Pharmaceuticals Inc.

Blueprint Medicines and Genentech, a member of the Roche Group

Lilly

Partners

American Society for Clinical Pathology

ProCE Banner

Partnered with the American Society for Clinical Pathology.

Faculty Disclosure

Primary Author

Juan C. Hernandez-Prera, MD

Associate Member
Department of Pathology
Section Head
Head & Neck - Endocrine Pathology
Department of Pathology
Moffitt Cancer Center
Tampa, Florida

Juan C. Hernandez-Prera, MD, has no relevant conflicts of interest to report.